PL3548633T3 - Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów - Google Patents

Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów

Info

Publication number
PL3548633T3
PL3548633T3 PL17817030.4T PL17817030T PL3548633T3 PL 3548633 T3 PL3548633 T3 PL 3548633T3 PL 17817030 T PL17817030 T PL 17817030T PL 3548633 T3 PL3548633 T3 PL 3548633T3
Authority
PL
Poland
Prior art keywords
chromsomal
epigenetic
interactions
application
cancer diagnostics
Prior art date
Application number
PL17817030.4T
Other languages
English (en)
Polish (pl)
Inventor
Francis Hector GRAND
Aroul Selvam Ramadass
Alexandre Akoulitchev
Ewan HUNTER
Original Assignee
Oxford BioDynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford BioDynamics PLC filed Critical Oxford BioDynamics PLC
Publication of PL3548633T3 publication Critical patent/PL3548633T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00—Reactions characterised by treatment of reaction samples
    • C12Q2523/10—Characterised by chemical treatment
    • C12Q2523/101—Crosslinking agents, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17817030.4T 2016-12-01 2017-11-30 Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów PL3548633T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428893P 2016-12-01 2016-12-01
PCT/GB2017/053615 WO2018100381A1 (en) 2016-12-01 2017-11-30 Application of epigenetic chromsomal interactions in cancer diagnostics

Publications (1)

Publication Number Publication Date
PL3548633T3 true PL3548633T3 (pl) 2024-04-02

Family

ID=60702831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17817030.4T PL3548633T3 (pl) 2016-12-01 2017-11-30 Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów

Country Status (12)

Country Link
US (2) US11560597B2 (enExample)
EP (2) EP3548633B1 (enExample)
JP (2) JP2019535295A (enExample)
KR (1) KR102481242B1 (enExample)
CN (1) CN110234769B (enExample)
AU (1) AU2017367245B2 (enExample)
CA (1) CA3045070A1 (enExample)
ES (1) ES2971286T3 (enExample)
MY (1) MY190153A (enExample)
PL (1) PL3548633T3 (enExample)
TW (1) TWI865427B (enExample)
WO (1) WO2018100381A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626699B (en) * 2019-05-08 2024-11-20 Oxford BioDynamics PLC Chromosome Conformation Markers of Prostate Cancer and Lymphoma
GB202008269D0 (en) * 2020-06-02 2020-07-15 Oxford Biodynamics Ltd Detecting a chromosome marker
CN118506860B (zh) * 2024-07-18 2024-10-08 广州女娲生命科技有限公司 药物表观遗传安全性评价的检测分析方法及系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006264564B2 (en) * 2005-07-04 2012-04-19 Erasmus University Medical Center Chromosome conformation capture-on-chip (4c) assay
GB0603251D0 (en) * 2006-02-17 2006-03-29 Isis Innovation DNA conformation
CN101688237A (zh) * 2007-01-11 2010-03-31 伊拉兹马斯大学医疗中心 环状染色体构象捕获(4c)
US20090117076A1 (en) * 2007-11-01 2009-05-07 Chen Lei L Methods For Treating Tumor Cells
GB0810051D0 (en) * 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
US9434985B2 (en) * 2008-09-25 2016-09-06 University Of Massachusetts Methods of identifying interactions between genomic loci
WO2010059742A1 (en) * 2008-11-18 2010-05-27 Collabrx, Inc. Individualized cancer treatment
AU2011274642B2 (en) * 2010-07-09 2015-05-21 Cergentis B.V. 3-d genomic region of interest sequencing strategies
CA2828099A1 (en) * 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2710146A2 (en) * 2011-05-18 2014-03-26 Life Technologies Corporation Chromosome conformation analysis
US20150182490A1 (en) * 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102827935B (zh) * 2012-08-29 2013-12-18 北京大学人民医院 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒
GB201320351D0 (en) * 2013-11-18 2014-01-01 Erasmus Universiteit Medisch Ct Method
JP2018527016A (ja) 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
US11339442B2 (en) * 2015-12-14 2022-05-24 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection

Also Published As

Publication number Publication date
EP3548633A1 (en) 2019-10-09
JP2023027076A (ja) 2023-03-01
JP2019535295A (ja) 2019-12-12
AU2017367245B2 (en) 2020-09-24
KR20190086569A (ko) 2019-07-22
JP7579003B2 (ja) 2024-11-07
TW201842190A (zh) 2018-12-01
NZ753716A (en) 2024-05-31
US11560597B2 (en) 2023-01-24
CA3045070A1 (en) 2018-06-07
EP3548633C0 (en) 2024-01-24
AU2017367245A1 (en) 2019-06-06
EP4357463A2 (en) 2024-04-24
MY190153A (en) 2022-03-31
WO2018100381A1 (en) 2018-06-07
US20190338367A1 (en) 2019-11-07
ES2971286T3 (es) 2024-06-04
TWI865427B (zh) 2024-12-11
EP4357463A3 (en) 2024-07-17
CN110234769B (zh) 2024-06-07
EP3548633B1 (en) 2024-01-24
US20230082230A1 (en) 2023-03-16
KR102481242B1 (ko) 2022-12-23
CN110234769A (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
IL281511B (en) High conductance process kit
SG11201606193RA (en) Biomolecule analysis kit and biomolecule analysis method
IL248819A0 (en) Translation during a conversation
IL256025A (en) Methods of diagnosing and treating cancer
SG11201704707PA (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
GB201616912D0 (en) Classification of cancer
GB201420859D0 (en) Tumour analysis
IL263123A (en) Cancer treatments
IL267315A (en) Methods of determining colorectal cancer status in an individual
GB2543200B (en) Junction-conveyed completion tooling and operations
GB201618200D0 (en) Simultaneous analysis of multiple components in well fluids
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
GB201608779D0 (en) Methods and compounds
SG10201913528PA (en) Methods of diagnosing cancer
PL3268337T3 (pl) Sposoby i zestawy do przygotowania kompleksów radionuklidu
SG10201605375YA (en) Sample holder and sample holder set
GB201608776D0 (en) Methods and compounds
SG10201504344VA (en) Component processing
GB201417661D0 (en) Agile Software Development Process And Results
SG11201700893WA (en) Biomolecule analyzer
PT3298165T (pt) Método e kit para diagnóstico de cancro colorretal
GB2546773B (en) Cancer
EP3535421C0 (en) DIAGNOSTIC PROCEDURES
GB201411393D0 (en) Agents and methods for determining colorectal cancer status
GB201611636D0 (en) Diagnostic methods and kits